JP2010512413A - アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法 - Google Patents

アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法 Download PDF

Info

Publication number
JP2010512413A
JP2010512413A JP2009541507A JP2009541507A JP2010512413A JP 2010512413 A JP2010512413 A JP 2010512413A JP 2009541507 A JP2009541507 A JP 2009541507A JP 2009541507 A JP2009541507 A JP 2009541507A JP 2010512413 A JP2010512413 A JP 2010512413A
Authority
JP
Japan
Prior art keywords
amphetamine
conjugate
composition
salt
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009541507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512413A5 (enExample
Inventor
ミクル，トラビス・シー
Original Assignee
ケムファーム・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケムファーム・インコーポレーテッド filed Critical ケムファーム・インコーポレーテッド
Publication of JP2010512413A publication Critical patent/JP2010512413A/ja
Publication of JP2010512413A5 publication Critical patent/JP2010512413A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
JP2009541507A 2006-12-11 2007-12-10 アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法 Withdrawn JP2010512413A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86937506P 2006-12-11 2006-12-11
PCT/US2007/087028 WO2008073918A1 (en) 2006-12-11 2007-12-10 Non-standard amino acid conjugates of amphetamine and processes for making and using the same

Publications (2)

Publication Number Publication Date
JP2010512413A true JP2010512413A (ja) 2010-04-22
JP2010512413A5 JP2010512413A5 (enExample) 2010-09-02

Family

ID=39512105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541507A Withdrawn JP2010512413A (ja) 2006-12-11 2007-12-10 アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法

Country Status (11)

Country Link
US (3) US7776917B2 (enExample)
EP (1) EP2101571B1 (enExample)
JP (1) JP2010512413A (enExample)
CN (1) CN101594778A (enExample)
AT (1) ATE509622T1 (enExample)
AU (1) AU2007333105A1 (enExample)
BR (1) BRPI0720105A2 (enExample)
CA (1) CA2672138A1 (enExample)
ES (1) ES2364865T3 (enExample)
IL (1) IL198930A0 (enExample)
WO (1) WO2008073918A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521641A (ja) * 2011-07-29 2014-08-28 ケムファーム， インコーポレイテッド ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス
JP2014521656A (ja) * 2011-07-28 2014-08-28 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US7776917B2 (en) 2006-12-11 2010-08-17 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
EP2109465B1 (en) 2007-02-08 2012-04-11 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
DE102007037478B3 (de) 2007-08-08 2008-04-30 Leifheit Ag Wäschetrockenständer
US8614346B2 (en) 2009-06-19 2013-12-24 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
EP3530268B1 (en) 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutic treatment
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
WO2017059459A1 (en) 2015-10-01 2017-04-06 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
US11007144B2 (en) 2016-11-15 2021-05-18 Klaria Pharma Holding Ab Pharmaceutical formulation
DK3551619T3 (da) 2016-12-11 2024-06-10 Zevra Therapeutics Inc Sammensætninger, der omfatter methylphenidat-prodrugs, fremgangsmåder til fremstilling og anvendelse heraf
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
JP2020516694A (ja) * 2017-04-10 2020-06-11 シャイアー ファーマシューティカルズ インコーポレイテッドＳｈｉｒｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． アンフェタミンプロドラッグを使用する治療方法
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
EP3692042A1 (en) * 2017-10-06 2020-08-12 Instituto de Medicina Molecular João Lobo Antunes Treatment of obesity-related conditions
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019199731A1 (en) * 2018-04-10 2019-10-17 Shire Pharmaceuticals Inc. Amphetamine prodrug and crystalline froms thereof
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2020181000A1 (en) * 2019-03-06 2020-09-10 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
JP2023505687A (ja) 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法
KR20230174213A (ko) 2021-03-09 2023-12-27 엔사이스 바이오사이언시즈 인크. 나파모스타트의 변형된 방출 조성물 및 그의 사용 방법
CN117715632A (zh) 2021-03-09 2024-03-15 恩赛斯生物科学股份有限公司 包含酶可裂解的前药和萘莫司他的组合物及其使用方法
EP4392402A4 (en) * 2021-08-24 2025-07-09 Mind Medicine Inc SYNTHETIC PATHWAYS TO ACCESS MDMA PRODRUGS USING CONTROLLED AND UNCONTROLLED INTERMEDIATES
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE539185A (enExample) * 1954-06-28
US2881113A (en) 1957-01-29 1959-04-07 Ortho Pharma Corp Therapeutically active compositions containing amphetamines
US2892753A (en) * 1957-02-26 1959-06-30 Boehringer Sohn Ingelheim Central nervous system stimulant
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
US6503950B1 (en) 1999-08-23 2003-01-07 David M. Ockert Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
HK1055078A1 (zh) 2000-06-09 2003-12-24 The Regents Of The University Of California 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
US6417184B1 (en) 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
AU2003219863C1 (en) 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
JP4898445B2 (ja) 2003-05-29 2012-03-14 シャイア エルエルシー 乱用抵抗性アンフェタミン化合物類
EP1931357A2 (en) 2005-09-13 2008-06-18 Shire LLC Prodrugs of phentermine
US7776917B2 (en) 2006-12-11 2010-08-17 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
EP2109465B1 (en) * 2007-02-08 2012-04-11 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521656A (ja) * 2011-07-28 2014-08-28 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法
JP2016222692A (ja) * 2011-07-28 2016-12-28 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法
JP2019112462A (ja) * 2011-07-28 2019-07-11 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法
JP2014521641A (ja) * 2011-07-29 2014-08-28 ケムファーム， インコーポレイテッド ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス

Also Published As

Publication number Publication date
IL198930A0 (en) 2010-02-17
US7776917B2 (en) 2010-08-17
AU2007333105A1 (en) 2008-06-19
WO2008073918A1 (en) 2008-06-19
US8101661B2 (en) 2012-01-24
US20090234018A1 (en) 2009-09-17
EP2101571B1 (en) 2011-05-18
US20100292336A1 (en) 2010-11-18
BRPI0720105A2 (pt) 2014-10-07
US20080139653A1 (en) 2008-06-12
ES2364865T3 (es) 2011-09-15
EP2101571A1 (en) 2009-09-23
HK1131518A1 (en) 2010-01-29
CN101594778A (zh) 2009-12-02
CA2672138A1 (en) 2008-06-19
EP2101571A4 (en) 2010-01-13
ATE509622T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
US7776917B2 (en) Non-standard amino acid conjugates of amphetamine and processes for making and using the same
EP2109465B1 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
JP4898445B2 (ja) 乱用抵抗性アンフェタミン化合物類
JP2014521641A (ja) ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス
JP7830540B2 (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
HK1131518B (en) Ornithine conjugates of amphetamine and processes for making and using the same
HK40077785A (en) D-amphetamine compounds, compositions, and processes for making and using the same
HK40078104A (en) D-amphetamine compounds, compositions, and processes for making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100713

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120530